The National Institute of Allergy and Infectious Diseases (NIAID) is conducting a research study aimed at stopping the spread of the Epstein-Barr virus (EBV), the main cause of mono. Join our compensated study and further EBV vaccine research today!
Epstein-Barr virus (EBV) infects more than 90% of the world’s population, and when adolescents and young adults contract the virus they are at risk of experiencing serious health complications like developing mono or certain cancers. Currently, there is no vaccine that prevents or treats EBV infection.
Join researchers and help stop the spread of EBV! Participation in this research study may inform future treatments. Compensation provided up to $2220.
Epstein-Barr virus (EBV) infects more than 90% of the world’s population, and when adolescents and young adults contract the virus they are at risk of experiencing serious health complications like developing mono or certain cancers. Currently, there is no vaccine that prevents or treats EBV infection.
Join researchers and help stop the spread of EBV! Participation in this research study may inform future treatments. Compensation provided up to $2220.
You may qualify for this study if you meet the following criteria.
Eligibility Criteria:
Once enrolled, this study involves: